Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6346939 | 1.00 | ALDH1A1 (0.40) | ALDH1A1ACEPOLBCAPN1LMNA | |
| SCHEMBL6347737 | 0.88 | ALDH1A1 (0.41) | ALDH1A1ACEPOLBCAPN1LMNA | |
| SCHEMBL6347742 | 0.88 | ALDH1A1 (0.41) | ALDH1A1ACEPOLBCAPN1LMNA | |
| SCHEMBL6356434 | 0.87 | ALDH1A1 (0.40) | ALDH1A1ACEPOLBCAPN1LMNA | |
| SCHEMBL6356439 | 0.87 | ALDH1A1 (0.40) | ALDH1A1ACEPOLBCAPN1LMNA | |
| SCHEMBL6358360 | 0.86 | ALDH1A1 (0.40) | ALDH1A1POLBCAPN1TP53MMP2 | |
| SCHEMBL6358371 | 0.86 | ALDH1A1 (0.40) | ALDH1A1POLBCAPN1TP53MMP2 | |
| SCHEMBL6351082 | 0.84 | ALDH1A1 (0.39) | ALDH1A1ACEPOLBCAPN1PSMB5 | |
| SCHEMBL6351077 | 0.84 | ALDH1A1 (0.39) | ALDH1A1ACEPOLBCAPN1PSMB5 | |
| SCHEMBL6348128 | 0.84 | MEN1 (0.39) | ALDH1A1ACECAPN1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960575-B2 | For use as inhibitors of chymase | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20040097496-A1 | Novel thiazine derivatives | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
| US-6713472-B1 | 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097496-A1 | Novel thiazine derivatives | CMA1, TPSD1, HRH4 | ALDH1A1 420/4885ACE 5/4885POLB 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.